SNY changes
Pick any two versions below to diff them.
- Price
- $40.29 → $40.97(+1.7%)
- Discount
- 29% to 42% → 28% to 41%(−1.0 pts)
- Recent events
- 2026-10-20: Sanofi and Teva showed 44-week data from the phase 2b extension study of duvakitug, their TL1A antibody, in ulcerative colitis and Crohn's disease. At the higher dose, 58% of ulcerative colitis patients were in clinical remission, and 55% of Crohn's disease patients had an endoscopic response. The study was small, and the companies call the data descriptive. Phase 3 studies continue in both diseases. 2026-10-01: Sanofi and Regeneron added four long-acting immunology antibodies to their alliance, among them REGN20423, an IL-13 antibody in phase 1. Regeneron receives $1 billion upfront and up to $7 billion in milestone payments, and the companies share costs and profits equally. 2026-09-14: Sanofi and Cheplapharm announced a plan under which Cheplapharm takes over 20 mature medicines, including the manufacture of Lovenox, and three manufacturing sites. In return, Sanofi receives a 26.4% equity stake in Cheplapharm. 2026-07-30: Sanofi reported Q2 2026 results. Sales rose 17.8% at constant exchange rates to €11,597 million, and Dupixent sales rose 37.6% to €5.2 billion. Business EPS rose 33.3% to €2.09, but IFRS EPS fell to €0.29 because of impairments. Sanofi raised its 2026 sales growth guidance to about 10% and said it expects Dupixent sales of about €25 billion in 2030. It completed its €1 billion share buyback. 2026-07-24: Sanofi stopped the development of amlitelimab in atopic dermatitis and will not submit it for approval, because it would not be a meaningful improvement over the standard of care. Sanofi also stopped the development of itepekimab and balinatunfib. 2026-07-21: Sanofi named a new, smaller Executive Committee from September 1, 2026. Olivier Charmeil left his role as head of General Medicines, and the General Counsel left the company. 2026-06-13: The FDA approved Tzield as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes. 2026-04-29: Shareholders appointed Belén Garijo as a director, and she became CEO of Sanofi. Olivier Charmeil had been interim CEO after Paul Hudson left in February 2026. 2026-04-23: Sanofi reported Q1 2026 results. Sales rose 13.6% at constant exchange rates to €10,509 million, Dupixent sales rose 30.8% to €4.2 billion, and business EPS rose 14.0% to €1.88. It completed the purchase of Dynavax.